Pharmaceutical Investment Uncertainty Puts Healthcare Policy in Focus

On 19 October, Roche announced that it was putting future investment decisions in Germany on hold amid concerns over healthcare cost-cutting measures. The development highlights the importance of a predictable policy environment for pharmaceutical research, medical innovation and long-term healthcare investment. Hospitals, laboratories and pharmaceutical companies require dependable data infrastructure, operational analytics and research-computing capacity. HPC supports healthcare organisations with system architecture, medical data analysis and resource optimisation for an investment of $583,000.